These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 2187266)

  • 21. [Naltrexone and prevention of opiate dependence relapse. An Italian experience].
    Cibin M; Gentile N; Ferri M; Gallimberti L
    Minerva Psichiatr; 1989; 30(2):93-8. PubMed ID: 2779401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Naltrexone renders one-session exposure therapy less effective: a controlled pilot study.
    Kozak AT; Spates CR; McChargue DE; Bailey KC; Schneider KL; Liepman MR
    J Anxiety Disord; 2007; 21(1):142-52. PubMed ID: 16647240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical use of naltrexone].
    Manzanares J
    Rev Med Univ Navarra; 1995; 40(2):78-84. PubMed ID: 7569550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
    Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
    Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naltrexone plus benzodiazepine aids abstinence in opioid-dependent patients.
    Stella L; D'Ambra C; Mazzeo F; Capuano A; Del Franco F; Avolio A; Ambrosino F
    Life Sci; 2005 Oct; 77(21):2717-22. PubMed ID: 15979652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Naltrexone for heroin dependence treatment in St. Petersburg, Russia.
    Krupitsky EM; Zvartau EE; Masalov DV; Tsoi MV; Burakov AM; Egorova VY; Didenko TY; Romanova TN; Ivanova EB; Bespalov AY; Verbitskaya EV; Neznanov NG; Grinenko AY; O'Brien CP; Woody GE
    J Subst Abuse Treat; 2004 Jun; 26(4):285-94. PubMed ID: 15182893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of the National Institute on Drug Abuse in the development of naltrexone.
    Ginzburg HM; Glass WJ
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):4-6. PubMed ID: 6088469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Naltrexone treatment for addicted health-care professionals: a collaborative private practice experience.
    Ling W; Wesson DR
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):46-8. PubMed ID: 6469936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Preventive therapy of opiate addiction with naltrexone].
    Sivolap IuP; Savchenkov VA
    Zh Nevrol Psikhiatr Im S S Korsakova; 1998; 98(11):22-5. PubMed ID: 9845936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outpatient opiate detoxification with clonidine.
    Washton AM; Resnick RB
    J Clin Psychiatry; 1982 Jun; 43(6 Pt 2):39-41. PubMed ID: 7085584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opiate addiction and the locus coeruleus. The clinical utility of clonidine, naltrexone, methadone, and buprenorphine.
    Gold MS
    Psychiatr Clin North Am; 1993 Mar; 16(1):61-73. PubMed ID: 8456048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Naltrexone in addicted business executives and physicians.
    Washton AM; Pottash AC; Gold MS
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):39-41. PubMed ID: 6088468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics.
    Verebey K
    NIDA Res Monogr; 1981; 28():147-58. PubMed ID: 6791001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Naltrexone-mediated opiate detoxification: a matter of terminology!
    Johnson TS; Carr M
    Addict Biol; 2003 Sep; 8(3):267-9. PubMed ID: 13129827
    [No Abstract]   [Full Text] [Related]  

  • 35. The effect of multiple family therapy on addict family functioning: a pilot study.
    Kosten TR; Hogan I; Jalali B; Steidl J; Kleber HD
    Adv Alcohol Subst Abuse; 1986; 5(3):51-62. PubMed ID: 3728193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multicentre study to introduce naltrexone for opiate dependence in Spain.
    García-Alonso F; Gutierrez M; San L; Bedate J; Forteza-Rei J; Rodríguez-Artalejo F; Palop R; López-Alvarez M; Pérez de los Cobos JC; Cami J
    Drug Alcohol Depend; 1989 Apr; 23(2):117-21. PubMed ID: 2702921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychosocial interventions and opioid detoxification for drug misuse: summary of NICE guidance.
    Pilling S; Strang J; Gerada C;
    BMJ; 2007 Jul; 335(7612):203-5. PubMed ID: 17656545
    [No Abstract]   [Full Text] [Related]  

  • 38. WITHDRAWN: Psychosocial treatment for opiate abuse and dependence.
    Mayet S; Farrell MF; Ferri M; Amato L; Davoli M
    Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD004330. PubMed ID: 24737603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Naltrexone-induced reduction of tobacco intake.
    Lerner AG; Oyffe I; Sigal M
    J Clin Psychiatry; 1998 Jan; 59(1):30-1. PubMed ID: 9491065
    [No Abstract]   [Full Text] [Related]  

  • 40. Drugs and demons.
    Parfitt T
    Lancet; 2004 Jul 31-Aug 6; 364(9432):403-4. PubMed ID: 15290838
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.